http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Sun, 18 Oct 2026 20:00:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List+Pro/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html <p>Citi is out with its preview into Q3 earnings of U.S. Smid biotech stocks, noting that a continued catalyst calendar and business development engagement have kept investor interest high in this part of the market. The firm has shared with investors key catalysts to watch.</p><p>While conversations on large-cap Biopharma tend to have policy and AI in focus, SMids “offer a more direct investment case around clinical data, regulatory progress, and launch execution.”</p><p>Also, while high interest rates are a valuation and financing headwind, the market sees the situation as temporary, which according to Citi, will allow IPO momentum to continue.</p><p>Given this http://www.streetinsider.com/Hot+List/U.S.+biotech+SMids%3A+Q3+earnings+preview/27199432.html Sun, 18 Oct 2026 20:00:00 -0400 ABOS AMLX BNTX FTH JAZZ KNSA KYMR MANE MRNA NAMS NUVB NVAX PTGX SRRK VOR